产品说明书

Niclosamide

Print
Chemical Structure| 50-65-7 同义名 : BAY2353;NSC 178296;Clonitralide, Fenasal, BAY 2353, BAY-2353, BAY2353, NSC 178296, NSC178296, NSC-178296, WR-46234, WR46234, WR 46234,;Niclocide
CAS号 : 50-65-7
货号 : A108674
分子式 : C13H8Cl2N2O4
纯度 : 98%
分子量 : 327.12
MDL号 : MFCD00057597
存储条件：

粉末 Sealed in dry,Room Temperature

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 4 mg/mL(12.23 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

DMF: 5 mg/mL(15.28 mM)，配合低频超声助溶
动物实验配方：
生物活性
靶点

  • STAT3

    STAT3, IC50:0.7 μM
描述 Niclosamide (BAY2353) is an orally active antihelminthic agent primarily employed in research related to parasitic infections[1]. Niclosamide also functions as a potent STAT3 inhibitor, demonstrating an IC50 of 0.25 μM in HeLa cells[4]. Additionally, Niclosamide exhibits anticancer properties and can inhibit DNA replication in Vero E6 cells[2].[3].[5]. Niclosamide, produced under Good Manufacturing Practice (GMP) guidelines as Niclosamide, is used in parasitic infection research and also serves as an auxiliary reagent for cell therapy manufacturing[1]. This formulation maintains its potency as a STAT3 inhibitor with an IC50 of 0.25 µM in HeLa cells[4]. Niclosamide shows anti-cancer activities, including the inhibition of DNA replication in Vero E6 cells[2].[3].[5].
细胞研究
细胞系 浓度 检测类型 检测时间 活动说明 数据源
CHO cells Function assay Cytoprotective activity against anthrax fusion toxin FP59-induced cell death in CHO cells assessed as cell viability by MTT reduction assay 19540764
HEK293 cells Function assay 8 h Inhibition of Wnt/beta-catenin in HEK293 cells assessed as inhibition of Wnt3A-stimulated TOPFlash activity after 8 hrs, IC50=0.34 μM 26272032
HEK293 cells Function assay 8 h Inhibition of Wnt3A/beta-casein signaling in HEK293 cells after 8 hrs by TOPflash reporter assay, IC50=0.4 μM 23453073
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01296958 Taenia Solium Taeniasis Not Applicable Completed - Peru ... 展开 >> San Marcos University Lima, Peru 收起 <<
NCT01189903 Asian Colorectal Cancer Patien... 展开 >>ts 收起 << Phase 2 Phase 3 Unknown - Singapore ... 展开 >> National University Hospital Singapore, Singapore, 119074 收起 <<
NCT00138359 Intestinal Parasitism Not Applicable Terminated - Peru ... 展开 >> Universidad Peruana Cayetano Heredia Lima, Peru 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

3.06mL

0.61mL

0.31mL

15.28mL

3.06mL

1.53mL

30.57mL

6.11mL

3.06mL
参考文献

[1]P Andrews, et al. The biology and toxicology of molluscicides, Bayluscide. Pharmacol Ther. 1982;19(2):245-95.

[2]Wei Chen, et al. Niclosamide: Beyond an antihelminthic drug. Cell Signal. 2018 Jan;41:89-96.

[3]Kei Satoh, et al. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma. Clin Cancer Res. 2016 Jul 15;22(14):3458-66.

[4]Xiaomei Ren, et al. Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway. ACS Med Chem Lett. 2010 Sep 7;1(9):454-9.

[5]Chang-Jer Wu, et al. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrob Agents Chemother. 2004 Jul;48(7):2693-6.

[6]Xu M, Lee EM, Wen Z, et al. Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen. Nat Med. 2016;22(10):1101-1107.

[7]Jiao Y, Chen C, Hu X, et al. Niclosamide and its derivative DK-520 inhibit RANKL-induced osteoclastogenesis. FEBS Open Bio. 2020;10(8):1685-1697. doi:10.1002/2211-5463.12921